ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

The Phase Relationship Between the Pyrazinamide Polymorphs α and γ

preprint
submitted on 19.12.2019 and posted on 23.12.2019 by Kangli Li, Gabin Gbabode, Maria Barrio, Josep-Lluis Tamarit, Marine Vergé-Depré, Benoît Robert, Ivo Rietveld

Pyrazinamide is an active pharmaceutical compound for the treatment of tuberculosis. It possesses at least four crystalline polymorphs. Polymorphism may cause solubility problems as the case of ritonavir has clearly demonstrated; however, polymorphs also provide opportunities to improve pharmaceutical formulations, in particular if the stable form is not very soluble. The four polymorphs of pyrazinamide constitute a rich system to investigate the usefulness of metastable forms and their stabilization. However, despite the existence of a number of papers on the polymorphism of pyrazinamide, well-defined equilibrium conditions between the polymorphs appear to be lacking. This paper focusses on the phase behavior of the so-called a and g polymorphs of pyrazinamide, its liquid phase and vapor phase. The melting points and enthalpies of both solid phases have been determined. The equilibrium temperature between a and g was experimentally found at 392(1) K. Moreover, vapor pressures and solubilities of both phases have been determined, clearly indicating that form a is the more stable form at room temperature. High-pressure thermal analysis and the topological pressure-temperature phase diagram demonstrate that the g form is stabilized by pressure and becomes stable at room temperature under a pressure of 260 MPa.

Funding

Region Normandie

Synchrotron Soleil

Mineco FIS2017-82625-P

Agaur DGU 2017SGR-42

History

Email Address of Submitting Author

ivo.rietveld@univ-rouen.fr

Institution

University of Rouen Normandie

Country

France

ORCID For Submitting Author

0000-0001-5987-3998

Declaration of Conflict of Interest

No competing interests

Exports